In This Section

Program

Please note: Posters will be available for on-demand viewing starting at 9:30 a.m. U.S. ET on Wednesday, February 3, 2021.

WEDNESDAY, FEBRUARY 3, 2021

THURSDAY, FEBRUARY 4, 2021

FRIDAY, FEBRUARY 5, 2021

Wednesday, february 3, 2021

Welcome and Opening Keynote Address             
10-10:30 A.m.

Welcome and Introduction of Keynote Speaker
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

Messenger RNA vaccines 
Ugur Sahin, BioNTech SE, Mainz, Germany
not eligible for CME credit

Break
10:30-10:45 A.M.
Symposium 1: Intersection of the Biology of COVID-19 and Cancer
10:45 A.M.-12:35 p.m.

Introduction
Dafna Bar-Sagi, NYU Langone Health, New York, New York

Coronaviral use of lysosomes for egress and its implications for the immune system
Nihal Altan-Bonnet, National Heart, Lung, and Blood Institute, Bethesda, Maryland

Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses*
Amy Moore, GO2 Foundation for Lung Cancer, San Carlos, California

The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score*
Gino Dettorre, Imperial College London, London, England

New frontiers in SARS-CoV-2 functional genomics
Nevile Sanjana, NYU Langone Health, New York, New York

Closing Remarks / Discussion

Symposium 2: Cancer Prevention and Early Detection during the COVID-19 Pandemic
10:45 A.M.-12:35 P.M.

Introduction
Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

Challenges to cancer screening during the COVID-19 pandemic
Mary E. Reid, Roswell Park Comprehensive Cancer Center, Buffalo, New York

The impact of resuming the breast cancer screening program in the Netherlands on breast cancer incidence and stage after its discontinuation due to the COVID-19 pandemic*
Sabine Siesling, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands

The impact of the COVID-19 pandemic on Barrett’s esophagus and esophago-gastric cancer*
Anita Lavery, Queen’s University Belfast, Belfast, Ireland

Drive By Flu-FIT: A novel way to mitigate the decrease in colorectal cancer screening during the COVID-19 pandemic*
Armenta Washington, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Breast cancer screening during the COVID-19 pandemic: Are we ready for a risk-based approach?
Katherine D. Crew, Columbia University, New York, New York

Closing Remarks / Discussion

Break
12:35-1 p.m.          
Forum 1: Cancer Trial Design/Experience During COVID-19
Moderator: Robert L. Ferris, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania
1-2 P.M.

Panelists:
Michael Kurilla, National Center for Advancing Translational Sciences, Bethesda, Maryland
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Worta McCaskill-Stevens, National Cancer Institute, Rockville, Maryland

Forum 2: When Should Patients With Cancer Be Vaccinated? 
Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
1-2 P.M.

Panelists: 
Grace Cordovano, Enlightening Results, West Caldwell, New Jersey
Jill Feldman, EGFR Resistors, Deerfield, Illinois
Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 
Jia Luo, Memorial Sloan Kettering Cancer Center, New York, New York 
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania 

Break
2-2:15 p.m.
Symposium 3: COVID-19 Immunology and Pathogenesis
2:15-4:05 P.M.

Introduction
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

Longitudinal immunological study of 200 COVID-19 patients
James R. Heath, Institute for Systems Biology, Seattle, Washington

Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study*
Lewis Au, The Francis Crick Institute, London, England

Cancer patients display diminished viral RNA clearance and altered T cell responses during SARS-CoV-2 infection*  
Michael Chiorazzi, Yale School of Medicine, New Haven, Connecticut

Spatial profiling of lung SARS-CoV-2 and influenza virus infection identifies virus specific host responses and gene signatures*
Arutha Kulasinghe, Queensland University of Technology, Brisbane, Australia

Immunology and animal models of COVID-19
Stanley Pearlman, University of Iowa, Iowa City, Iowa

Closing Remarks / Discussion

Symposium 4: COVID-19 Long-term Effects and Impact on Cancer Survivorship
2:15-4:05 P.M.

Introduction
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California

Long-term effects and impact of COVID-19 pandemic on cancer survivorship
Larissa Nekhlyudov, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

Effects of demographic and behavioral factors on social isolation in a cancer center population during COVID-19 pandemic*
Shelley Tworoger, Moffitt Cancer Center, Tampa, Florida

Impact of the COVID-19 pandemic on social and health behaviors among rural and urban cancer patients at Huntsman Cancer Institute (HCI)*
Bailee Daniels, Huntsman Cancer Institute, Salt Lake City, Utah

Closing Remarks / Discussion

Thursday, February 4, 2021

Keynote Address           
10-10:30 a.m.

Introduction of Keynote Speaker 
Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 

Vaccine development during the COVID-19 pandemic
Peter Marks, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Break
10:30-10:45 a.m.
Symposium 5: Cancer Drug Repurposing to Treat COVID-19
10:45 A.M.-12:35 P.M.

Introduction
Fabrice Barlesi, INSERM U1030 – Gustave Roussy Institute, Villejuif, France

Host factor–targeted drug discovery for SARS-CoV-2 through an international collaboration
Nevan J. Krogan, UCSF School of Medicine, San Francisco, California

Plant viral nanoparticle-based adjuvants for cancer immunotherapy and COVID-19 vaccines*
Nicole Steinmetz, University of California, San Diego, California

Storming the castle: Repurposing treatments for COVID-19
David Fajgenbaum, University of Pennsylvania, Philadelphia, Pennsylvania

Closing Remarks / Discussion     

Symposium 6: Continuity of Cancer Care
10:45 A.M.-12:35 P.M.

Introduction
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Impact of the COVID-19 pandemic on oncology care delivery: From screening to surveillance
Trisha Wise-Draper, University of Cincinnati, Cincinnati, Ohio

Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study*
Sheena Bhalla, Icahn School of Medicine at Mount Sinai, New York, New York

Outcomes of COVID-19 in patients with cancer: Results of a prospective observational comparison of routine screening strategy versus testing based on clinical suspicion*
Zhuoer Xie, Mayo Clinic, Rochester, Minnesota

Telehealth experiences of adolescent and young adult cancer patients and survivors during the COVID-19 pandemic*
Karely Mann, Huntsman Cancer Institute, Salt Lake City, Utah

Recommendations supporting continuity of care: Landscape, perspectives, limitations, and open questions
Giuseppe Curigliano, University of Milan, Milan, Italy

Closing Remarks / Discussion

Break
12:35-1 p.m.
Forum 3: Adaptive Trial Design / ICU
Moderator: Marko Spasic, Parker Institute for Cancer Immunotherapy, San Francisco, California
1-2 p.m.

Panelists:
Derek C. Angus, University of Pittsburgh, Pittsburgh, Pennsylvania
Laura J. Esserman, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California
Robin Mogg, Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts

Forum 4: Telehealth
Moderator: Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
1-2 P.M.

Panelists:
Elizabeth A. Krupinski, Emory University, Atlanta, Georgia
Hanna K. Sanoff, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Break
2-2:15 p.m.
Symposium 7: COVID-19 Vaccines
2:15-4:05 P.M.

Introduction
Deepta Bhattacharya, University of Arizona Cancer Center, Tucson, Arizona

Development of the Moderna COVID-19 vaccine
Randall N. Hyer, Moderna, Cambridge, Massachusetts

SARS-CoV-2 mRNA-LNP vaccines elicit potent germinal center responses associated with neutralizing antibody generation
Michela Locci, University of Pennsylvania, Philadelphia, Pennsylvania

Closing Remarks / Discussion

Symposium 8: Critical Care and Outpatient Management of COVID-19 and Cancer Patients
2:15-4:05 P.M.

Introduction
Louis P. Voigt, Memorial Sloan Kettering Cancer Center, New York, New York

Risks and outcomes of COVID-19 in patients with cancer
Mini Kamboj, Memorial Sloan Kettering Cancer Center, New York, New York

Caring for patients with cancer during COVID-19: Outpatient operations
Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, New York

COVID-19: The MD Anderson Cancer Center experience
Cristina Gutierrez, The University of Texas MD Anderson Cancer Center, Houston, Texas

Managing COVID-19 severe pneumonia in cancer patients
Elie Azoulay, Hôpital St Louis, Paris, France 

Waiting for COVID-19: Nothing like Godot
Sanjay Chawla, Memorial Sloan Kettering Cancer Center, New York, New York

Closing Remarks / Discussion

Friday, FEBRUARY 5, 2021

Keynote Address           
10-10:30 a.m.

Introduction of Keynote Speaker
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Prolonged virus shedding and virus-induced lymphopenia are detrimental in cancer patients
Laurence Zitvogel, Gustave Roussy, Villejuif, France

Break
10:30-10:45 a.m.       
Symposium 9: Effects of Cancer Treatments on COVID-19
10:45 A.M.-12:35 P.M.

Introduction
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer
Santosha A. Vardhana, Memorial Sloan Kettering Cancer Center, New York, New York

High incidence of persistent Covid-19 among patients with lymphoma treated with B-cell depleting immunotherapy*
Sylvain Lamure, CHU Montpellier, Montpellier, France

Real-world data analysis of patients with genitourinary cancers receiving systemic anticancer treatment during the COVID-19 pandemic at Guy’s Cancer Centre: A single-center retrospective study in the UK*
Christina Karampera, Guy’s and St Thomas’ NHS Foundation Trust, London, England

Asymptomatic detection of COVID-19 among cancer patients receiving infusional anti-cancer therapy*
Justin Shaya, UC San Diego Moores Cancer Center, San Diego, California

Prognostic factors in cancer patients with COVID-19: Focus on systemic therapies
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts

Closing Remarks / Discussion


Symposium 10: Health Inequities and Disparities in the COVID-19 Pandemic
10:45 A.M.-12:35 P.M.

Introduction
John M. Carethers, University of Michigan, Ann Arbor, Michigan

Cancer health equity & COVID-19
Karen M. Winkfield, Meharry-Vanderbilt Alliance, Nashville, Tennessee

Financial hardship and mental health among cancer survivors during the COVID-19 pandemic: An analysis of the US COVID Impact Survey*
Jessica Islam, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Adolescent and young adult cancer patient and survivor employment changes during COVID-19 are associated with financial toxicity*
Austin Waters, Huntsman Cancer Institute, Salt Lake City, Utah

Disparities in food insecurity among cancer survivors during the U.S. COVID-19 pandemic*
Marlene Camacho-Rivera, SUNY Downstate Health Sciences University, Brooklyn, New York

Economic and insurance challenges from the COVID-19 pandemic for individuals with cancer
Michael T. Halpern, National Cancer Institute, Bethesda, Maryland

Closing Remarks / Discussion

Break
12:35-1 P.M.   
Forum 5: Workforce Issues
Moderator: Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, Maryland
1-2 p.m.

Panelists:
Dinah S. Singer, National Cancer Institute, Bethesda, Maryland
Cheryl L. Willman, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
Robert A. Winn, VCU Massey Cancer Center, Richmond, Virginia

Break
2-2:15 p.m.
Symposium 11: Risk Factors and Comorbidities Resulting in Adverse Outcomes FOR CANCER PATIENTS WITH COVID-19
2:15-4:05 P.M.

Introduction
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York

Impact of COVID-19 on recipients of cellular therapies
Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center,  New York, New York

Factors associated with developing COVID-19 among cancer patients in New York City*
Monica Chen, Columbia University, New York, New York

The impact of COVID-19 in the cancer population stratified by age: A real-world data study from Guy’s Cancer Center*
Rushan Sylva, Guy’s and St. Thomas’ NHS Foundation Trust, London, England

Using CXR-Net to detect COVID-19 and non-COVID-19 patients*
Abdulah Haikal, Wayne State University School of Medicine, Detroit, Michigan

Risks of severe COVID19 infection in patients with solid tumors
Tian Zhang, Duke University School of Medicine, Durham, North Carolina

Closing Remarks / Discussion

Symposium 12: Epidemiology and Registries of COVID-19 and Cancer
2:15-4:05 P.M.

Introduction
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California

Quantifying the impact of COVID-19 on cancer care: Pathology volume change in SEER cancer registries*
Todd Golden, National Cancer Institute, Bethesda, Maryland

Comprehensive meta-analysis of COVID-19 mortality rates for 22 cancer subtypes from the Reboot: COVID-Cancer Project, an interactive resource with aggregated data from 21,839 cancer patients*
Catherine Del Vecchio Fitz, Reboot Rx, Boston, Massachusetts

Clinical and demographic characteristics associated with shorter time to COVID-19 death*
Maria J. Monroy-Iglesias, King’s College London, London, England

Covid-19 disease in patients with lung cancer in Spain: GRAVID Lung Cancer Patients Disease (GRAVID study)*
Jose Maria Mazarico Gallego, Hospital Universitario 12 de Octubre, Madrid, Spain

Prevalence of COVID-19 in asymptomatic cancer patients on active systemic treatment in a public Brazilian hospital: The impact of socioeconomic status*
Luiza Fadul, Hospital de Base de São José do Rio Preto, Sao Jose do Rio Preto, Brazil

Social Determinants of Health (SDOH) barriers as predictors of intent to vaccinate for COVID-19 in a vulnerable population*
Beth A. Jones, Yale University School of Public Health, New Haven, Connecticut

Closing Remarks / Discussion

Break
4:05-4:20 P.M.
Closing Session: Emerging Topics
Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
4:20-5:30 p.m.  

Panelists: 
Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

*Short talk from proffered paper